Interleukin-1 (IL-1) and IL-6 are key mediators driving local inflammation and myeloid cell recruitment, contributing to impaired healing, adverse remodelling, and poor outcomes.1 On this background, IL-1 receptor antagonists have been tested as therapeutic targets in patients with MI. This evidence concerns the gene IL6 and myocardial infarction.